Stockholm, June 12th, 2019 – Today ContextVision held a company presentation at Carnegie in Stockholm, Sweden. Fredrik Palm gave an update of the company’s development and shared the company’s future direction. Please find a PDF-version of the presentation here. For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or […]
Stockholm, May 29, 2019 The ContextVision AB:s Profit Sharing Foundation has sold and purchased shares in ContextVision AB in accordance with the rules related to the foundation. The ContextVision AB:s Profit Sharing Foundation has sold 23,700 shares during the period April 3 – May 23, at an average price of 72,35 NOK/share, in […]
On the 8th of May 2019, ContextVision held its ordinary Shareholders’ Annual General Meeting in Stockholm. The annual financial report regarding 2018 was presented and approved by the AGM. Disposition of financial results according to the proposal of the Board of Directors was approved. The Managing Director and the Board of Directors were discharged […]
ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, reported strong sales in Q1, reaching 21.1 MSEK, 9% higher than the first quarter last year. The company reports positive feedback from user tests within digital pathology and continues to proceed with product development for this fast-growing market.
ContextVision Earns Acclaim from Frost & Sullivan for Its AI-powered INIFY™ Prostate Cancer Screening Platform
Based on its recent analysis of the European prostate cancer screening market, Frost & Sullivan recognises the Stockholm-based ContextVision AB with the 2019 European Technology Leadership Award for its INIFY™ Prostate platform.
ContextVision will have exclusive rights to the scanning cohort and access to anonymized associated clinical data - with cleared and structured histopathological descriptions, diagnosis and outcome data - for the defined patient cohorts and all commercial rights from output based on the data.The agreement gives ContextVision an opportunity to create AI-based decision support tools that will help doctors make more accurate treatment decisions. Today, many cancer patients suffer from life impairing side effects from treatments they did not need while other patients do not get treatment which is necessary.
STOCKHOLM – 27. of March 2019 – ContextVision, a medical technology company specializing in image analysis and artificial intelligence, is pleased to announce that Fredrik Palm will become CEO of the Company as of April 1, 2019. Fredrik Palm has since 2012 been the Company’s V.P. of sales and was instrumental in growing sales significantly under his […]
March 11st, 2019 – An article about ContextVision has been published in the Norwegian business newspaper Finansavisen (in Norwegian only). Please find a link here. For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43